Yoshinobu Takakura1, Yuki Takahashi1, Yoshihiko Watanabe2 and Makiya Nishikawa1
1Department of Biopharmaceutics and Drug Metabolism, 2Department of Molecular Microbiology, Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto, 606-8501, Japan email@example.com
New cancer therapeutic system has been developed by utilizing interferon-γ (IFNγ) gene delivery. Plasmid vectors that express IFNγ for a long period of time were constructed. Separately, genetically modified IFNγ fusion proteins were designed to control the tissue distribution of IFNγ. IFNγ fused with mouse serum albumin showed an extended retention in the serum after in vivo gene transfer. These changes in the expression profile or in the tissue distribution were proved effective in increasing the therapeutic potency of IFNγ gene delivery.